Clinical Trial Update: CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) [Phase 2]

View source ↗

Summary

Phase 2 trial update of CRLX101 (NLG207) in combination with bevacizumab for metastatic renal cell carcinoma compared to standard of care.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CRLX101

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED